Introduction {#s01}
============

Cutaneous melanoma incidence continually increases in developed countries, particularly in fair-skinned individuals^[@b1]-[@b4]^. Recent data^[@b5]^ indicated that prevalence of melanoma in Northern Italy is two fold higher than in Southern Italy and with Central Italy showing prevalence at intermediate level. High incidence rates were particularly registered in the Northeast Friuli-Venezia Giulia region (19.6/100,000/year in men; 16.4/100,000/year in women)^[@b6]^, implying that geographically detailed studies should be performed regarding melanoma risk factors^[@b7]^.

Melanoma is the leading cause of mortality among skin cancer patients with low survival rates^[@b8]^. Although new therapeutic treatments are available^[@b9]^, early detection and surgery remain the main treatment options. Therefore, every new discovery on melanoma biological pathways presents opportunity in improving management and treatment options. Considerable preclinical and epidemiologic data suggest that vitamin D may play an important role in cancer pathogenesis and progression^[@b10]^. Numerous preclinical studies specifically indicated that exposure of cancer cells to high concentrations of vitamin D metabolites halts progression through the cell cycle, induces apoptosis, and slows down or stops tumor growth^[@b11]^. Vitamin D also enhances antitumor activity of some cytotoxic anticancer agents in *in vivo* preclinical models^[@b12]^. Anti-proliferative effects of vitamin D for cancer prevention and treatment were explored in several malignancies, including skin, breast, prostate, colorectal, and other cancers^[@b8],[@b13]-[@b18]^. Numerous epidemiological studies supported the hypothesis that individuals with lower serum vitamin D levels feature higher exposure risk to different cancers^[@b12]^. Current literature suggests the chemopreventive role of vitamin D by acting against initiation and progression of tumorigenesis^[@b8],[@b12]-[@b18]^. Despite the stronger consensus on protective role of vitamin D against cancer, particularly by reduction of mortality rate, its therapeutic function for cancer patients remains debatable^[@b10],[@b19]^. Remarkably, a recent meta-analysis showed that vitamin D supplementation minimally affects total cancer incidence, even when total cancer mortality is significantly reduced^[@b20]^.

Vitamin D receptor (VDR) is a nuclear transcription factor belonging to the nuclear receptor superfamily that binds 1α, 25-dihydroxyvitamin D (calcitriol) with high affinity and specificity^[@b19]^. Upon binding to the active form of vitamin D, VDR translocates from cytoplasm into the nucleus and binds to vitamin D responsive elements (VDREs), thus up- or down-regulating hundreds of genes directly controlled by vitamin D^[@b19],[@b21],[@b22]^. Increasing evidence showed pleiotropic hormonal effects of vitamin D on calcium and skeletal metabolism, immunological responses, detoxification, oxidative stress, cancer-related metabolic pathways, proliferation, and cell differentiation^[@b18],[@b19],[@b21]^.

VDR is abundantly expressed in the skin^[@b19],[@b21]^. Some VDR expression was also reported to occur in cultured melanoma cells^[@b11],[@b13],[@b14],[@b23]^. Intermittent sun exposure or ultraviolet (UV) radiation and sunburns are known environmental risk factors for melanoma^[@b24],[@b25]^. However, chronic and continuous UV radiation exposure activates vitamin D biosynthesis, which in turn can develop a protective action against tumoral proliferation^[@b8],[@b12],[@b16],[@b25]^. Four recently discovered mechanisms may underlie actions of VDR as a tumor suppressor in the skin^[@b10]^.

Human *VDR* gene is located on chromosome 12q12-q14 and comprises 11 exons and 11 introns^[@b26]^. Genetic variants of *VDR* may modulate its actions, with FokI, BsmI, ApaI, and TaqI being the most studied single-nucleotide polymorphisms (SNPs)^[@b26]-[@b28]^. *VDR*-FokI polymorphism is a functional SNP that extends lengths of the receptor protein from 424 to 427 amino acid residues. BsmI, ApaI, and TaqI polymorphisms are located in the 3′ terminal region of the *VDR* gene and do not affect protein sequence of the VDR receptor. FokI polymorphism is reported not to be in linkage disequilibrium with the other three polymorphisms. Instead, BsmI, ApaI, and TaqI polymorphisms are reported to be in linkage disequilibrium to a variable extent; thus, combined genotypes including two or three of these polymorphisms were investigated in literature^[@b26],[@b28],[@b29]^. Some evidence suggested that genotypes FF, BB, tt, and the combined genotype BBAAtt may be associated with increased expression of VDR, which in turn regulates actions of vitamin D^[@b26]-[@b28]^. Roles of *VDR* polymorphisms in melanoma were evaluated in some recent studies and meta-analyses^[@b30]-[@b37]^. However, associations of *VDR* polymorphisms with skin cancer risk remain insufficiently characterized^[@b30],[@b31],[@b36]^.

At present, no study examined *VDR* polymorphisms and VDR expression in melanoma cells of excised tissues from patients.

Thus far, only one cohort of 69 Polish melanoma patients was investigated by two studies for VDR expression in tumor tissues^[@b38],[@b39]^. VDR expression progressively decreases from normal skin to melanocytic nevi to melanomas^[@b38]^, suggesting the relationship between VDR expression and melanoma prognosis^[@b39]^. Brożyna and colleagues^[@b38]^ observed reduced expression levels of VDR in skin surrounding nevi and melanomas as opposed to normal skin.

Advances in melanoma treatment can be achieved through developments in understanding of melanoma risk factors, genomics, and molecular pathogenesis^[@b31],[@b40]^.

By immunohistochemical staining of primary cutaneous melanoma tissues, we investigated VDR expression in relation to characteristics, melanoma histological grading, and metastatic stage of patients. We also explored the association of four *VDR* SNPs- FokI-rs2228570 C\>T located in exon 2, BsmI-rs1544410 G\>A located in intron 8, ApaI-rs7975232 T\>G located in intron 8, and TaqI-rs731236 T\>C located in exon 9- with VDR expression levels in cutaneous malignant melanoma tissues.

Patients and methods {#s02}
====================

Patients {#s02.01}
--------

Enrolment and clinical visits of all study participants were performed at the Udine University-Hospital Dermatology Clinic. Diagnostic procedures were conducted according to routine protocols. All participants signed a written informed consent. The Udine Institutional Ethical Committee approved the study protocol in accordance to the Declaration of Helsinki.

Seventy-four (39 males, 35 females, age range: 29-82 years) unrelated patients (hospitalized or outpatients) who consecutively underwent surgical excision of cutaneous melanoma were enrolled based on a retrospective design. Inclusion criteria were as follows: melanoma different from that in *in situ* only, absence of mucosal melanomas, patient is a resident of Friuli-Venezia Giulia region (Northern Italy), and absence of major chronic diseases, such as autoimmune diseases, and type 1 diabetes.

Assessment of melanoma diagnosis and patient stage classification were performed by clinical/histological findings as described by Balch et al.^[@b41]^. For patients with multiple melanomas, we examined only the first main melanoma according to histological assessment of major primary tumor grading, and primary melanoma characteristics were accounted for study analyses.

Questionnaires were used to collect information from each participant; data obtained included demographic and lifestyle characteristics and medical and family history of melanoma. Body mass index (BMI) was determined by ratio of weight (kg) to squared height (m).

Immunohistochemical staining and evaluation of VDR expression {#s02.02}
-------------------------------------------------------------

Slides stained with hematoxylin and eosin were reviewed for each case from formalin-fixed and paraffin-embedded blocks and were selected for VDR immunohistochemical staining. Immunohistochemistry was performed on 5 µm thick paraffin sections as follows: after dewaxing, rehydration and endogenous peroxidase quenching with 3% v/v H ~2~O ~2~ in methanol for 15 min, antigen retrieval in 0.01 M citrate buffer at 98°C water bath for 40 min, application and incubation of primary antibody (VDR mouse monoclonal D-6, sc-13133, Santa Cruz Biotechnology, Texas, USA) at 1:200 dilution 1 h at room temperature^[@b42],[@b43]^, incubation with peroxidase-based EnVision+ /Horseradish peroxidase (Dako A/S, Glostrup, Denmark) for 30 min at room temperature, and treatment with diaminobenzidine for 3 min^[@b44]^. The sections were then counterstained with Mayer's hematoxylin, dehydrated, and mounted. VDR expression was evaluated on tumor cells (nuclear and cytoplasmic staining) of the whole section. Immunolabeled sections were viewed under Nikon Eclipse 80i light microscope at 25× magnification, and a semi-quantitative evaluation was performed to determine VDR expression levels in malignant melanoma cells (nuclear and cytoplasmic staining). Staining of sweat gland cells, which consistently showed strong and diffused positivity throughout all samples, was used as positive reference. The term "emboli" indicates tumoral invasion of vascular cells observed in slide specimens. Melanoma specimens were reviewed by two pathologists involved in the study but were unaware of all other clinical and molecular data during evaluation. Our categorization choices were based on the following considerations: A) when melanomas feature 100% VDR-positive cells, all tumor cells are possibly responsive to vitamin D stimulation; B) when 0% cells are positive for VDR expression, virtually all tumor cells do not respond to vitamin D stimulation; C) aside from extreme conditions, a cut off at median percentage of positive cells can be reasonably used for evaluating the half of samples with higher*vs*. the half of samples with lower VDR expression. Therefore, results were ranked based on percentage of cells positive for VDR expression (irrespective of staining intensity). Cytoplasmic VDR expression ranged from 0% to 100%, with a median value at 20.0%. We categorized variables as follows: 100% cytoplasmic VDR-expression-positive cells versus all remaining melanomas; \>20% cytoplasmic VDR-expression-positive cells (high VDR expression) *vs*. ≤20% positive cells (low VDR expression); and absent (0% positive cells) *vs*. present (\>0% positive cells) VDR expression. Only 11 out of 74 cases (14.9%) showed nuclear VDR-positive immunostaining, and all these cases were categorized into \>20% cytoplasmic VDR-expression-positive cells. Given the low number of melanoma specimens showing VDR expression detected in nuclei, this parameter was not further analyzed.

Determination of *VDR* gene polymorphisms {#s02.03}
-----------------------------------------

Determination of SNP *VDR*-FokI (C\>T),*VDR*-BsmI (G\>A),*VDR*-ApaI (T\>G),*VDR*-TaqI (T\>C) was performed as previously described^[@b29],[@b45]^ after extraction of genomic DNA from ethylenediaminetetraacetic-acid -venous blood samples^[@b46]^. Absence or presence of restriction site was denoted by a capital or lower letter, respectively: "F" and "f" for FokI, "B" and "b" for BsmI, "A" and "a" for ApaI, and "T" and "t" for TaqI endonucleases^[@b28],[@b29]^. FokI, BsmI, ApaI and TaqI polymorphisms of *VDR* were studied using previously tested primers^[@b29],[@b45]^ to amplify appropriate DNA fragments. FokI enzyme (Euroclone, Milano, Italy) digestion of 265 bp amplified DNA was used to determine FokI restriction fragment length polymorphism (RFLP) yielding 196 and 69 bp fragments in the presence of f allele^[@b46]^. To analyze BsmI polymorphism, the resulting amplified 825 bp polymerase chain reaction (PCR) fragment was digested with BsmI restriction enzyme (Euroclone, Milano, Italy), generating 650 and 175 bp fragments in the presence of b allele^[@b29]^. ApaI digestion of the 740 bp amplified DNA was used to determine both ApaI and TaqI RFLP, generating 530 and 210 bp fragments in the presence of a allele. Digestion with TaqI of the 740 bp PCR fragment generated 290, 245, and 205 bp fragments in the presence of t allele and 495 and 245 bp fragments in its absence (T allele) owing to an additional monomorphic TaqI site^[@b29]^. DNA fragments were separated by polyacrylamide gel electrophoresis.

Statistical analysis {#s02.04}
--------------------

Kolmogorov-Smirnov test was used to assess normal data distribution. Percentage of VDR-positive cells by immunohistochemical staining was not normally distributed. Thus, median values and ranges were reported for this variable. Mann-Whitney U test was used to assess differences between groups. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to determine association of groups with different VDR expression and melanoma characteristics, alleles, genotypes, and combined genotypes. Our study was explorative as no previous investigation determined frequencies of VDR polymorphisms in melanoma patients according to immunohistochemical findings of VDR expression Prior to study enrolment, we evaluated that a number of 70 subjects fitted the 80% power at an alpha level of 0.05 to detect differences between high (above the median) and low VDR expression melanoma groups whether OR value equals 3 or more for a SNP site^[@b47]^. Deviation tests from Hardy-Weinberg equilibrium (HWE) were performed using a separate Chi-square distribution for each SNP^[@b29]^. Linkage disequilibrium (LD) between SNPs was determined as described^[@b29]^. Two-sided significance level was set at 0.05, and *P* values ≤ 0.10 were considered as a tendency to be significant. Statistical software SPSS (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.

Results {#s03}
=======

VDR immunohistochemical staining {#s03.01}
--------------------------------

A significant variability in VDR immunohistochemical staining was observed in cytoplasm of melanoma cells, with 16.2% (12/74) of patients tested positive for 100% melanoma cell staining, whereas 20.3% (15/74) were tested negative. Median percentage value of VDR-positive staining reached 20.0%. [**Figures 1**](#Figure1){ref-type="fig"}, [**2**](#Figure2){ref-type="fig"}, and [**3**](#Figure3){ref-type="fig"} display representative images of VDR immunohistochemical staining in excised tissues from patients with primary cutaneous melanoma, showing 100% staining, intermediate staining, and no staining, respectively.

![Representative image of VDR protein expression in cutaneous melanoma tissue. Melanoma showing diffuse positivity for VDR expression. Eroded epidermis (H&E staining, 25×. Bar indicates 50 μm).](cbm-14-2-162-1){#Figure1}

![Representative image of VDR protein expression in cutaneous melanoma tissue. Melanoma featuring tumor-infiltrating lymphocytes (TILs). Intraepidermal component of lesion (at the bottom of image) shows strong positivity for VDR expression (H&E staining, 25×. Bar indicates 50 μm).](cbm-14-2-162-2){#Figure2}

![Representative image of VDR protein expression in cutaneous melanoma tissue. Melanoma featuring TILs. In this case, melanoma cells nesting in the dermis are negative throughout the whole lesion (H&E staining, 25×. Bar indicates 50 μm).](cbm-14-2-162-3){#Figure3}

Patients and melanoma characteristics according to VDR expression {#s03.02}
-----------------------------------------------------------------

All 74 (35 females and 39 males) cutaneous melanoma patients were white residents in Northern Italy. Average age at melanoma diagnosis was 52.1±12.7 years, with 27% (20/74) of patients exhibiting metastatic melanoma (i.e., stages III and IV), and all showed Clark level higher than Clark I invasion.

[**Table 1**](#Table1){ref-type="table"} shows the main clinical characteristics of melanoma patients and compares three different binary categories according to percentage of tumor cells positive for VDR staining: a) 100% positive*vs*. \<100% positive, b) over 20% (median value) positive (high VDR expression) *vs*. ≤20% positive (low VDR expression), and c) absence *vs*. presence of VDR-positive cells. Complete data on ORs and CIs are reported on [**Table S1**](#TableS1){ref-type="table"}. Age of melanoma diagnosis, gender, BMI, and smoking did not differ between compared groups. Differences were not significant in comparison of 12 subjects with 100% VDR-positive cells *vs*. 62 subjects with \<100% VDR-positive cells. The following statically significant differences were observed during comparison of 36 melanomas with high VDR expression *vs*. 38 melanomas with low VDR expression: stage I was more frequent in the former (63.9% *vs*. 39.5%, OR=2.71, CI=1.06--6.95, *P*=0.036), whereas stage II was less frequent (11.1% *vs*. 31.6%, OR=0.27, CI=0.08--0.94, *P*=0.033); the former presents a lower mean Breslow thickness (1.23±0.88*vs*. 2.27±1.97 mm,*P*=0.008) and more frequent Breslow thickness of \<1.00 mm (50.0% *vs*. 26.3%, OR=2.80, CI=1.06--7.41, *P*=0.036) and less frequent Breslow thickness ≥1.01 mm (50.0% *vs*. 77.8%, OR=0.36, CI=0.13--0.95, *P*=0.036). A higher frequency of Clark II invasion (38.9% *vs*. 15.8%, OR=3.39, CI=1.13--10.2, *P*=0.025) was observed in high- than low-VDR-expression group. Superficial spreading was present in 61.1% of melanomas with high VDR expression *vs*. 39.5% of low-VDR-expression melanomas, where this difference did not reach significant *P* values (*P*=0.063). In comparing absence *vs*. presence of VDR-positive immunohistochemical staining of melanoma cells, the only significant finding was a higher frequency of stage II A in the former*vs*. the latter (26.7% *vs*. 5.1%, OR=6.79, CI=1.33--34.7, *P*=0.028) (all sub-stage data are shown in [**Table S1**](#TableS1){ref-type="table"}).

###### 

Clinical characteristics of 74 consecutively enrolled melanoma patients and comparison between groups of 100% VDR-positive cells (*n*=12) *vs*. \<100% ( *n*=62); over the median (\>20%) VDR-positive cells (*n*=36) *vs*. below or equal the median (≤20%) (*n*=38); and absence of VDR-positive cell (*n*=15) *vs*. remaining cases with detected VDR expression (*n*=59)

  Characteristics                               All melanoma patients (*n*=74)   100% VDR- positive cells (*n*=12)   \<100% VDR- positive cells (*n*=62)   *P*=100% *vs*. \<100% VDR- positive   \>20%^a^ VDR- positive cells (*n*=36)   ≤20% VDR- positive cells (*n*=38)   *P*\>20%*vs*. ≤20% VDR- positive   VDR absence (0% positive) (*n*=15)   VDR presence (\>0% positive) (*n*=59)   PVDR absence *vs.* presence
  --------------------------------------------- -------------------------------- ----------------------------------- ------------------------------------- ------------------------------------- --------------------------------------- ----------------------------------- ---------------------------------- ------------------------------------ --------------------------------------- -----------------------------
  Age at melanoma diagnosis, years, mean ± SD   52.1±12.7                        49.8±13.0                           52.7±12.9                             0.519^a^                              51.7±13.9                               52.8±12.0                           0.770^a^                           51.5±14.5                            52.5±12.6                               0.767^a^
  Age \<50 years at melanoma diagnosis          31 (41.9)                        6 (50.0)                            25 (40.3)                             0.534                                 16 (44.4)                               15 (39.5)                           0.665                              7 (46.7)                             24 (40.7)                               0.675
  BMI, kg/m^2^, mean ± SD                       25.8±4.0                         25.0±4.6                            25.9±3.9                              0.412^a^                              26.0±4.3                                25.6±3.8                            0.804^a^                           25.7±2.6                             25.8±4.3                                0.762^a^
  Male                                          39 (52.7)                        6 (50.0)                            33 (53.2)                             0.838                                 20 (55.6)                               19 (50.0)                           0.632                              9 (60.0)                             30 (50.8)                               0.526
  Smoker                                        11 (14.9)                        2 (16.7)                            9 (14.5)                              1.000                                 4 (11.1)                                7 (18.4)                            0.377                              2 (13.3)                             9 (15.3)                                1.000
  Stage I                                       38 (51.4)                        6 (50.0)                            32 (51.6)                             0.919                                 23 (63.9)                               15 (39.5)                           0.036                              6 (40.0)                             32 (54.2)                               0.325
  Stage II                                      16 (21.6)                        2 (16.7)                            14 (22.6)                             1.000                                 4 (11.1)                                12 (31.6)                           0.033                              6 (40.0)                             10 (16.9)                               0.077
  Stage III                                     10 (13.5)                        3 (25.0)                            7 (11.3)                              0.351                                 6 (16.7)                                4 (10.5)                            0.510                              1 (6.7)                              9 (15.3)                                0.676
  Stage IV                                      10 (13.5)                        1 (8.3)                             9 (14.5)                              1.000                                 3 (8.3)                                 7 (18.4)                            0.310                              2 (13.3)                             8 (13.6)                                1.000
  Metastatic melanoma (Stage III +IV)           20 (27.0)                        4 (33.3)                            16 (25.8)                             0.724                                 9 (25.0)                                11 (28.9)                           0.702                              3 (20.0)                             17 (28.8)                               0.746
  Trunk                                         47 (63.5)                        5 (41.7)                            42 (67.7)                             0.108                                 24 (66.7)                               23 (60.5)                           0.583                              7 (46.7)                             40 (67.8)                               0.129
  Upper limb                                    6 (8.1)                          2 (16.7)                            4 (6.5)                               0.249                                 2 (5.6)                                 4 (10.5)                            0.675                              3 (20.0)                             3 (5.1)                                 0.093
  \>Lower limb                                  14 (18.9)                        3 (25.0)                            11 (17.7)                             0.687                                 7 (19.4)                                7 (18.4)                            0.911                              4 (26.7)                             10 (16.9)                               0.463
  Hands/feet                                    5 (6.8)                          2 (16.7)                            3 (4.8)                               0.183                                 2 (5.6)                                 3 (7.9)                             1.000                              0 (--)                               5 (8.5)                                 0.576
  Head/neck                                     2 (2.7)                          0 (--)                              2 (3.2)                               1.000                                 1 (2.8)                                 1 (2.6)                             1.000                              1 (6.7)                              1 (1.7)                                 0.367
  Superficial spreading                         37 (50.0)                        7 (58.3)                            30 (48.4)                             0.528                                 22 (61.1)                               15 (39.5)                           0.063                              6 (40.0)                             31 (52.5)                               0.386
  Nodular                                       31 (41.9)                        4 (33.3)                            27 (43.5)                             0.512                                 12 (33.3)                               19 (50.0)                           0.146                              8 (53.3)                             23 (39.0)                               0.314
  Acral lentiginous                             3 (4.1)                          1 (8.3)                             2 (3.2)                               0.417                                 1 (2.8)                                 2 (5.3)                             1.000                              0 (--)                               3 (5.1)                                 1.000
  Spitzoide                                     2 (2.7)                          0 (--)                              2 (3.2)                               1.000                                 1 (2.8)                                 1 (2.6)                             1.000                              1 (6.7)                              1 (1.7)                                 0.367
  Others                                        3 (4.1)                          0 (--)                              3 (4.8)                               1.000                                 0 (--)                                  3 (7.9)                             0.240                              0 (--)                               3 (5.1)                                 1.000
  Breslow thickness, mm, mean ± SD              1.77±1.62                        1.34±0.94                           1.85±1.71                             0.416^a^                              1.23±0.88                               2.27±1.97                           0.008^a^                           2.16±1.88                            1.66±1.55                               0.145^a^
  Continued                                                                                                                                                                                                                                                                                                                                                                                  

###### 

Clinical characteristics of 74 consecutively enrolled melanoma patients and comparison between groups of 100% VDR-positive cells (*n*=12) *vs*. \<100% ( *n*=62); over the median (\>20%) VDR-positive cell (*n*=36) *vs*. below or equal the median (≤20%) (*n*=38); and absence of VDR-positive cell (*n*=15) *vs*. remaining cases with detected VDR expression (*n*=59)

  Characteristics                               All melanoma patients (*n*=74)   100% VDR-positive cells (*n*=12)   \<100% VDR-positive cells (*n*=62)   OR (CI)100% *vs*. \< 100% VDR-positive   *P*=100% *vs*. \< 100% VDR-positive   \>20%^a^ VDR-positive cells (*n*=36)   ≤20% VDR-positive cells (*n*=38)   OR (CI)\>20%*vs*. ≤ 20% VDR-positive   *P*\>20%*vs*. ≤ 20% VDR-positive   VDR absence (0% positive)(*n*=15)   VDR presence (\>0% positive)(*n*=59)   OR (CI)VDR absence *vs*. presence   PVDR absence *vs*. presence
  --------------------------------------------- -------------------------------- ---------------------------------- ------------------------------------ ---------------------------------------- ------------------------------------- -------------------------------------- ---------------------------------- -------------------------------------- ---------------------------------- ----------------------------------- -------------------------------------- ----------------------------------- -----------------------------
  Age at melanoma diagnosis, years, mean ± SD   52.1±12.7                        49.8±13.0                          52.7±12.9                            --                                       0.519^a^                              51.7±13.9                              52.8±12.0                          --                                     0.770^a^                           51.5±14.5                           52.5±12.6                              --                                  0.767^a^
  Age \<50 years at melanoma diagnosis          31 (41.9)                        6 (50.0)                           25 (40.3)                            1.48 (0.43--5.11)                        0.534                                 16 (44.4)                              15 (39.5)                          1.23 (0.49--3.09)                      0.665                              7 (46.7)                            24 (40.7)                              1.28 (0.41--3.99)                   0.675
  BMI, kg/m^2^, mean ± SD                       25.8±4.0                         25.0±4.6                           25.9±3.9                             --                                       0.412^a^                              26.0±4.3                               25.6±3.8                           --                                     0.804^a^                           25.7±2.6                            25.8±4.3                               --                                  0.762^a^
  Male                                          39 (52.7)                        6 (50.0)                           33 (53.2)                            0.88 (0.25--3.03)                        0.838                                 20 (55.6)                              19 (50.0)                          1.25 (0.50--3.12)                      0.632                              9 (60.0)                            30 (50.8)                              1.45 (0.46--4.59)                   0.526
  Smoker                                        11 (14.9)                        2 (16.7)                           9 (14.5)                             1.18 (0.22--6.28)                        1.000                                 4 (11.1)                               7 (18.4)                           0.55 (0.15--2.08)                      0.377                              2 (13.3)                            9 (15.3)                               0.85 (0.16--4.45)                   1.000
  Stage I                                       38 (51.4)                        6 (50.0)                           32 (51.6)                            0.94 (0.27--3.23)                        0.919                                 23 (63.9)                              15 (39.5)                          2.71 (1.06--6.95)                      0.036                              6 (40.0)                            32 (54.2)                              0.56 (0.18--1.78)                   0.325
  Stage I A                                     23 (31.1)                        4 (33.3)                           19 (30.6)                            1.13 (0.30--4.22)                        1.000                                 15 (41.7)                              8 (21.1)                           2.68 (0.96--7.45)                      0.055                              3 (20.0)                            20 (33.9)                              0.49 (0.12--1.93)                   0.365
  Stage I B                                     15 (20.3)                        2 (16.7)                           13 (21.0)                            0.75 (0.15--3.87)                        1.000                                 8 (22.2)                               7 (18.4)                           1.26 (0.41--3.94)                      0.684                              3 (20.0)                            12 (20.3)                              0.98 (0.24--4.03)                   1.000
  Stage II                                      16 (21.6)                        2 (16.7)                           14 (22.6)                            0.69 (0.13--3.50)                        1.000                                 4 (11.1)                               12 (31.6)                          0.27 (0.08--0.94)                      0.033                              6 (40.0)                            10 (16.9)                              3.27 (0.95--11.3)                   0.077
  Stage II A                                    7 (9.5)                          0 (--)                             7 (11.3)                             --^b^                                    0.590                                 0 (--)                                 7 (18.4)                           \-^b^                                  0.012                              4 (26.7)                            3 (5.1)                                6.79 (1.33--34.7)                   0.028
  Stage II B                                    9 (12.2)                         2 (16.7)                           7 (11.3)                             1.57 (0.28--8.69)                        0.633                                 4 (11.1)                               5 (13.2)                           0.82 (0.20--3.35)                      1.000                              2 (13.3)                            7 (11.9)                               1.14 (0.21--6.16)                   1.000
  Stage II C                                    0 (--)                           0 (--)                             0 (--)                               --^b^                                    --^b^                                 0 (--)                                 0 (--)                             --^b^                                  --^b^                              0 (--)                              0 (--)                                 --^b^                               --^b^
  Stage III                                     10 (13.5)                        3 (25.0)                           7 (11.3)                             2.62 (0.57--12.0)                        0.351                                 6 (16.7)                               4 (10.5)                           1.70 (0.44--6.60)                      0.510                              1 (6.7)                             9 (15.3)                               0.40 (0.05--3.40)                   0.676
  Stage III A                                   4 (5.4)                          1 (8.3)                            3 (4.8)                              1.79 (0.17--18.8)                        0.515                                 3 (8.3)                                1 (2.6)                            3.36 (0.33--33.9)                      0.351                              0 (--)                              4 (6.8)                                --^b^                               0.576
  Stage III B                                   3 (4.1)                          0 (--)                             3 (4.8)                              --^b^                                    1.000                                 0 (--)                                 3 (7.9)                            --^b^                                  0.240                              1 (6.7)                             2 (3.4)                                2.04 (0.17--24.1)                   0.499
  Stage III C                                   3 (4.1)                          2 (16.7)                           1 (1.6)                              12.2 (1.01--147)                         0.067                                 3 (8.3)                                0 (--)                             --^b^                                  0.110                              0 (--)                              3 (5.1)                                --^b^                               1.000
  Continued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

Overall, as shown in [**Table 1**](#Table1){ref-type="table"}, none of the tumor markers commonly associated with severe prognosis and metastatic stage were associated with VDR immunohistochemical staining; these markers included ulceration, mitosis \>1, absence of tumor-infiltrating lymphocytes (TILs), emboli, and epithelioid variants. The presence of multiple melanomas, additional skin, non-skin cancers, and melanoma familiarity did not correlate with VDR immunohistochemical staining.

By further analysis, median VDR expression did not differ between 20 metastatic melanomas (median: 17.5%, range: 0%--100% VDR-positive cells) and 54 non-metastatic melanomas (median: 25.0%, range: 0%--100% VDR-positive cells), with *P*=0.796. Significant *P* value (*P*=0.095) was not observed in differences in median values of VDR expression of stage I melanomas compared with those of stages II+III+IV. Median values of VDR expression of Clark II (in our cohort, none of melanomas showed Clark I invasion) melanomas were significantly higher compared with Clark III+IV+V levels (median: 70.0%, range: 0%--100% *vs*. median: 10.0%, range: 0%--100% VDR-positive cells, *P*=0.019). A significant *P* value was not observed in differences in median values of VDR expression in superficially spreading melanomas compared with the remaining ones (*P*=0.075).

Patient and melanoma characteristics according to *VDR* polymorphisms {#s03.03}
---------------------------------------------------------------------

[**Table 2**](#Table2){ref-type="table"} shows *VDR* polymorphism genotypes, alleles, and combined genotype frequencies in all 74 patients and in groups of melanomas categorized according to VDR immunohistochemical staining. Each*VDR* polymorphism of FokI, BsmI, ApaI, and TaqI was in HWE. FokI SNP was not in LD with other SNPs. BsmI was in LD with ApaI and TaqI, and ApaI was in LD with TaqI. Thus, for further analyses, we considered binary and ternary combination of genotypes comprising BsmI, ApaI and TaqI polymorphisms. As observed in other studies^[@b26],[@b29]^, not all theoretically possible binary and ternary combination of genotypes were observed; thus, [**Table 2**](#Table2){ref-type="table"} reports only combined genotypes with at least one confirmed finding.

###### 

Genotype and allele of ApaI, VDR-polymorphism, and BsmI-ApaI, ApaI-TaqI, BsmI-ApaI-TaqI combined genotypes of 74 melanoma patients and comparisons between groups of 100% VDR-positive cells (*n*=12) *vs*. \<100% ( *n*=62); over the median (\>20%) VDR-positive cells (*n*=36) *vs*. below or equal the median (≤20%) (*n*=38); and absence of VDR-positive cell (*n*=15) *vs*. remaining cases with detected VDR expression (*n*=59)

  *VDR* genotype or combined genotype   All melanoma patients (*n*=74)   100% VDR-positive cells (*n*=12)   \<100% VDR-positive cells (*n*=62)   *P*=100% *vs*.\<100% VDR-positive   \>20%^a^ VDR-positive cells (*n*=36)   ≤20% VDR-positive cells (*n*=38)   *P*\>20%*vs*. ≤20% VDR-positive   VDR absence (0% positive)(*n*=15)   VDR presence (\>0% positive)(*n*=59)   PVDR absence *vs*. presence
  ------------------------------------- -------------------------------- ---------------------------------- ------------------------------------ ----------------------------------- -------------------------------------- ---------------------------------- --------------------------------- ----------------------------------- -------------------------------------- -----------------------------
  ApaI genotype                                                                                                                                                                                                                                                                                                                                                             
  AA                                    30 (40.5)                        8 (66.7)                           22 (35.5)                            0.058                               13 (36.1)                              17 (44.7)                          0.450                             8 (53.3)                            22 (37.3)                              0.258
  Aa                                    36 (48.6)                        4 (33.3)                           32 (51.6)                            0.246                               22 (61.1)                              14 (36.8)                          0.037                             5 (33.3)                            31 (52.5)                              0.184
  aa                                    8 (10.8)                         0 (--)                             8 (12.9)                             0.339                               1 (2.8)                                7 (18.4)                           0.056                             2 (13.3)                            6 (10.2)                               0.660
  A allele                              96/148 (64.9)                    20/24 (83.3)                       76/124 (61.3)                        0.038                               48/72 (66.7)                           48/76 (63.2)                       0.655                             21/30 (70.0)                        75/118 (63.6)                          0.509
  a allele                              52/148 (35.1)                    4/24 (16.7)                        48/124 (38.7)                        0.038                               24/72 (33.3)                           28/76 (36.8)                       0.655                             9/30 (30.0)                         43/118 (36.4)                          0.509
  BsmI-ApaI combined genotype                                                                                                                                                                                                                                                                                                                                               
  BBAA                                  23 (31.1)                        5 (41.7)                           18 (29.0)                            0.498                               9 (25.0)                               14 (36.8)                          0.271                             6 (40.0)                            17 (28.8)                              0.533
  BbAA                                  5 (6.8)                          3 (25.0)                           2 (3.2)                              0.028                               4 (11.1)                               1 (2.6)                            0.194                             1 (6.7)                             4 (6.8)                                1.000
  BbAa                                  31 (41.9)                        1 (8.3)                            30 (48.4)                            0.010                               18 (50.0)                              13 (34.2)                          0.169                             5 (33.3)                            26 (44.1)                              0.452
  Bbaa                                  2 (2.7)                          0 (--)                             2 (3.2)                              1.000                               0 (--)                                 2 (5.3)                            0.494                             0 (--)                              2 (3.4)                                1.000
  bbAA                                  2 (2.7)                          0 (--)                             2 (3.2)                              1.000                               0 (--)                                 2 (5.3)                            0.494                             1 (6.7)                             1 (1.7)                                0.367
  bbAa                                  5 (6.8)                          3 (25.0)                           2 (3.2)                              0.028                               4 (11.1)                               1 (2.6)                            0.194                             0 (--)                              5 (8.5)                                0.576
  bbaa                                  6 (8.1)                          0 (--)                             6 (9.7)                              0.581                               1 (2.8)                                5 (13.2)                           0.200                             2 (13.3)                            4 (6.8)                                0.595
  ApaI-TaqI combined genotype                                                                                                                                                                                                                                                                                                                                               
  AATT                                  4 (5.4)                          0 (--)                             4 (6.5)                              1.000                               0 (--)                                 4 (10.5)                           0.115                             3 (20.0)                            1 (1.7)                                0.025
  AATt                                  14 (18.9)                        6 (50.0)                           8 (12.9)                             0.008                               9 (25.0)                               5 (13.2)                           0.194                             4 (26.7)                            10 (16.9)                              0.463
  AAtt                                  12 (16.2)                        2 (16.7)                           10 (16.1)                            1.000                               4 (11.1)                               8 (21.1)                           0.246                             1 (6.7)                             11 (18.6)                              0.439
  AaTT                                  12 (16.2)                        3 (25.0)                           9 (14.5)                             0.399                               9 (25.0)                               3 (7.9)                            0.046                             1 (6.7)                             11 (18.6)                              0.439
  AaTt                                  24 (32.4)                        1 (8.3)                            23 (37.1)                            0.089                               13 (36.1)                              11 (28.9)                          0.511                             4 (26.7)                            20 (33.9)                              0.761
  aaTT                                  8 (10.8)                         0 (--)                             8 (12.9)                             0.339                               1 (2.8)                                7 (18.4)                           0.056                             2 (13.3)                            6 (10.2)                               0.660
  BsmI-ApaI-TaqI combined genotype                                                                                                                                                                                                                                                                                                                                          
  BBAATT                                1 (1.4)                          0 (--)                             1 (1.6)                              1.000                               0 (--)                                 1 (2.6)                            1.000                             1 (6.7)                             0 (--)                                 0.203
  BBAATt                                10 (13.5)                        3 (25.0)                           7 (11.3)                             0.351                               5 (13.9)                               5 (13.2)                           1.000                             4 (26.7)                            6 (10.2)                               0.110
  BBAAtt                                12 (16.2)                        2 (16.7)                           10 (16.1)                            1.000                               4 (11.1)                               8 (21.1)                           0.246                             1 (6.7)                             11 (18.6)                              0.439
  BbAATt                                4 (5.4)                          3 (25.0)                           1 (1.6)                              0.012                               4 (11.1)                               0 (--)                             0.051                             0 (--)                              4 (6.8)                                0.576
  BbAATT                                1 (1.4)                          0 (--)                             1 (1.6)                              1.000                               0 (--)                                 1 (2.6)                            1.000                             1 (6.7)                             0 (--)                                 0.203
  BbAaTT                                7 (9.5)                          0 (--)                             7 (11.3)                             0.590                               5 (13.9)                               2 (5.3)                            0.255                             1 (6.7)                             6 (10.2)                               1.000
  BbAaTt                                24 (32.4)                        1 (8.3)                            23 (37.1)                            0.089                               13 (36.1)                              11 (28.9)                          0.511                             4 (26.7)                            20 (33.9)                              0.761
  BbaaTT                                2 (2.7)                          0 (--)                             2 (3.2)                              1.000                               0 (--)                                 2 (5.3)                            0.494                             0 (--)                              2 (3.4)                                1.000
  bbAATT                                2 (2.7)                          0 (--)                             2 (3.2)                              1.000                               0 (--)                                 2 (5.3)                            0.494                             1 (6.7)                             1 (1.7)                                0.367
  bbAaTT                                5 (6.8)                          3 (25.0)                           2 (3.2)                              0.028                               4 (11.1)                               1 (2.6)                            0.194                             0 (--)                              5 (8.5)                                0.576
  bbaaTT                                6 (8.1)                          0 (--)                             6 (9.7)                              0.581                               1 (2.8)                                5 (13.2)                           0.200                             2 (13.3)                            4 (6.8)                                0.595

Differences between VDR expression groups were not significant for single FokI, BsmI, and TaqI genotypes and alleles, and BsmI-TaqI combined genotypes (data shown in [**Table S3**](#TableS3){ref-type="table"}).

As reported in [**Table 2**](#Table2){ref-type="table"} (data comprising all ORs and CIs are shown in [**Table S2**](#TableS2){ref-type="table"}. [**Table S1**](#TableS2){ref-type="table"} to [**Table S3**](#TableS3){ref-type="table"} in the supplementary materials, available with the full text of this article at www.cancerbiomed.org), heterozygous Aa genotype was more frequent in melanomas with high than low VDR expression (61.1% *vs*. 36.8%, OR=2.69, CI=1.05--6.90, *P*=0.037). A allele was found in 83.3% of 100% VDR-positive melanomas and in 61.3% of those with \<100% VDR-positive cells (OR=3.16, CI=1.02--9.80, *P*=0.038).

###### 

Genotype and allele of ApaI, VDR-polymorphism, and BsmI-ApaI, ApaI-TaqI, BsmI-ApaI-TaqI combined genotypes of 74 melanoma patients and comparisons between groups of 100% VDR-positive cells (*n*=12) *vs*. \<100% ( *n*=62); over the median (\>20%) VDR-positive cells (*n*=36) *vs*. below or equal the median (≤20%) (*n*=38); and absence of VDR-positive cell (*n*=15) *vs*. remaining cases with detected VDR expression (*n*=59)

  *VDR* genotype or combined genotype   All melanoma patients (*n*=74)   100% VDR-positive cells (*n*=12)   \<100% VDR-positive cells (*n*=62)   OR (CI) 100% *vs*. \<100% VDR-positive   *P*=100% *vs*. \<100% VDR-positive   \>20%^a^ VDR-positive cells (*n*=36)   ≤20% VDR-positive cells (*n*=38)   OR (CI)\>20%*vs*. ≤20% VDR-positive   *P*\>20%*vs*.≤20% VDR-positive   VDR absence (0% positive)(*n*=15)   VDR presence (\>0% positive)(*n*=59)   OR (CI) VDR absencevs. presence   PVDR absence *vs*. presence
  ------------------------------------- -------------------------------- ---------------------------------- ------------------------------------ ---------------------------------------- ------------------------------------ -------------------------------------- ---------------------------------- ------------------------------------- -------------------------------- ----------------------------------- -------------------------------------- --------------------------------- -----------------------------
  ApaI genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  AA                                    30 (40.5)                        8 (66.7)                           22 (35.5)                            3.64 (0.98--13.5)                        0.058                                13 (36.1)                              17 (44.7)                          0.70 (0.27--1.78)                     0.450                            8 (53.3)                            22 (37.3)                              1.92 (0.61--6.03)                 0.258
  Aa                                    36 (48.6)                        4 (33.3)                           32 (51.6)                            0.47 (0.13--1.72)                        0.246                                22 (61.1)                              14 (36.8)                          2.69 (1.05--6.90)                     0.037                            5 (33.3)                            31 (52.5)                              0.45 (0.14--1.48)                 0.184
  aa                                    8 (10.8)                         0 (--)                             8 (12.9)                             --^b^                                    0.339                                1 (2.8)                                7 (18.4)                           0.13 (0.01--1.09)                     0.056                            2 (13.3)                            6 (10.2)                               1.36 (0.24--7.52)                 0.660
  A allele                              96/148 (64.9)                    20/24 (83.3)                       76/124 (61.3)                        3.16 (1.02--9.80)                        0.038                                48/72 (66.7)                           48/76 (63.2)                       1.17 (0.59--2.29)                     0.655                            21/30 (70.0)                        75/118 (63.6)                          1.34 (0.56--3.18)                 0.509
  a allele                              52/148 (35.1)                    4/24 (16.7)                        48/124 (38.7)                        0.32 (0.10--0.98)                        0.038                                24/72 (33.3)                           28/76 (36.8)                       0.86 (0.44--1.69)                     0.655                            9/30 (30.0)                         43/118 (36.4)                          0.75 (0.31--1.78)                 0.509
  BsmI-ApaI combined genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  BBAA                                  23 (31.1)                        5 (41.7)                           18 (29.0)                            1.75 (0.49--6.23)                        0.498                                9 (25.0)                               14 (36.8)                          0.57 (0.21--1.56)                     0.271                            6 (40.0)                            17 (28.8)                              1.65 (0.51--5.34)                 0.533
  BbAA                                  5 (6.8)                          3 (25.0)                           2 (3.2)                              10.0 (1.46--68.3)                        0.028                                4 (11.1)                               1 (2.6)                            4.62 (0.49--43.5)                     0.194                            1 (6.7)                             4 (6.8)                                0.98 (0.10--9.49)                 1.000
  BbAa                                  31 (41.9)                        1 (8.3)                            30 (48.4)                            0.10 (0.01--0.80)                        0.010                                18 (50.0)                              13 (34.2)                          1.92 (0.75--4.90)                     0.169                            5 (33.3)                            26 (44.1)                              0.63 (0.19--2.09)                 0.452
  Bbaa                                  2 (2.7)                          0 (--)                             2 (3.2)                              --^b^                                    1.000                                0 (--)                                 2 (5.3)                            --^b^                                 0.494                            0 (--)                              2 (3.4)                                --^b^                             1.000
  bbAA                                  2 (2.7)                          0 (--)                             2 (3.2)                              --^b^                                    1.000                                0 (--)                                 2 (5.3)                            --^b^                                 0.494                            1 (6.7)                             1 (1.7)                                4.14 (0.24--70.4)                 0.367
  bbAa                                  5 (6.8)                          3 (25.0)                           2 (3.2)                              10.0 (1.46--68.3)                        0.028                                4 (11.1)                               1 (2.6)                            4.62 (0.49--43.5)                     0.194                            0 (--)                              5 (8.5)                                --^b^                             0.576
  bbaa                                  6 (8.1)                          0 (--)                             6 (9.7)                              --^b^                                    0.581                                1 (2.8)                                5 (13.2)                           0.19 (0.02--1.70)                     0.200                            2 (13.3)                            4 (6.8)                                2.11 (0.35--12.8)                 0.595
  ApaI-TaqI combined genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  AATT                                  4 (5.4)                          0 (--)                             4 (6.5)                              --^b^                                    1.000                                0 (--)                                 4 (10.5)                           --^b^                                 0.115                            3 (20.0)                            1 (1.7)                                14.5 (1.39--152)                  0.025
  AATt                                  14 (18.9)                        6 (50.0)                           8 (12.9)                             6.75 (1.74--26.1)                        0.008                                9 (25.0)                               5 (13.2)                           2.20 (0.66--7.35)                     0.194                            4 (26.7)                            10 (16.9)                              1.78 (0.47--6.74)                 0.463
  AAtt                                  12 (16.2)                        2 (16.7)                           10 (16.1)                            1.04 (0.20--5.48)                        1.000                                4 (11.1)                               8 (21.1)                           0.47 (0.13--1.72)                     0.246                            1 (6.7)                             11 (18.6)                              0.31 (0.04--2.63)                 0.439
  AaTT                                  12 (16.2)                        3 (25.0)                           9 (14.5)                             1.96 (0.44--8.67)                        0.399                                9 (25.0)                               3 (7.9)                            3.89 (0.96--15.8)                     0.046                            1 (6.7)                             11 (18.6)                              0.31 (0.04--2.63)                 0.439
  AaTt                                  24 (32.4)                        1 (8.3)                            23 (37.1)                            0.15 (0.02--1.27)                        0.089\^                              13 (36.1)                              11 (28.9)                          1.39 (0.52--3.68)                     0.511                            4 (26.7)                            20 (33.9)                              0.71 (0.20--2.51)                 0.761
  aaTT                                  8 (10.8)                         0 (--)                             8 (12.9)                             --^b^                                    0.339                                1 (2.8)                                7 (18.4)                           0.13 (0.01--1.09)                     0.056                            2 (13.3)                            6 (10.2)                               1.36 (0.24--7.52)                 0.660
  BsmI-ApaI-TaqI combined genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  BBAATT                                1 (1.4)                          0 (--)                             1 (1.6)                              --^b^                                    1.000                                0 (--)                                 1 (2.6)                            --^b^                                 1.000                            1 (6.7)                             0 (--)                                 --^b^                             0.203
  BBAATt                                10 (13.5)                        3 (25.0)                           7 (11.3)                             2.62 (0.57--12.0)                        0.351                                5 (13.9)                               5 (13.2)                           1.06 (0.28--4.04)                     1.000                            4 (26.7)                            6 (10.2)                               3.21 (0.77--13.3)                 0.110
  Continued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

###### 

Genotype and allele characteristics of FokI, BsmI, and TaqI VDR-polymorphisms and BsmI-TaqI haplotypes of 74 melanoma patients and comparisons between groups of 100% VDR-positive cells (*n*=12) *vs*. \<100% ( *n*=62); over the median (\>20%) VDR-positive cells (*n*=36) versus below or equal the median (≤20%) (*n*=38); and absence of VDR-positive cell (*n*=15) versus remaining cases with detected VDR expression (*n*=59)

  *VDR* genotype or combined genotype   All melanoma patients (*n*=74)   100% VDR-positive cells (*n*=12)   \<100% VDR-positive cells (*n*=62)   OR (CI) 100% *vs*. \< 100% VDR-positive   *P*=100% *vs*. \< 100% VDR-positive   \>20%^a^ VDR-positive cells (*n*=36)   ≤20% VDR-positive cells (*n*=38)   OR (CI)\>20%*vs*. ≤ 20% VDR-positive   *P*\>20%*vs*. ≤ 20% VDR-positive   VDR absence (0% positive)(*n*=15)   VDR presence (\>0% positive)(*n*=59)   OR (CI) VDR absence *vs*. presence   PVDR absence *vs*. presence
  ------------------------------------- -------------------------------- ---------------------------------- ------------------------------------ ----------------------------------------- ------------------------------------- -------------------------------------- ---------------------------------- -------------------------------------- ---------------------------------- ----------------------------------- -------------------------------------- ------------------------------------ -----------------------------
  FokI genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  FF                                    32 (43.2)                        5 (41.7)                           27 (43.5)                            0.93 (0.26--3.24)                         0.904                                 16 (44.4)                              16 (42.1)                          1.10 (0.44--2.76)                      0.839                              7 (46.7)                            25 (42.4)                              1.19 (0.38--3.71)                    0.764
  Ff                                    33 (44.6)                        5 (41.7)                           28 (45.2)                            0.87 (0.25--3.03)                         0.824                                 14 (38.9)                              19 (50.0)                          0.64 (0.25--1.60)                      0.337                              6 (40.0)                            27 (45.8)                              0.79 (0.25--2.50)                    0.688
  ff                                    9 (12.2)                         2 (16.7)                           7 (11.3)                             1.57 (0.28--8.69)                         0.633                                 6 (16.7)                               3 (7.9)                            2.33 (0.54--10.1)                      0.302                              2 (13.3)                            7 (11.9)                               1.14 (0.21--6.16)                    1.000
  F allele                              97/148 (65.5)                    15/24 (62.5)                       82/124 (66.1)                        0.85 (0.34--2.11)                         0.732                                 46/72 (63.9)                           51/76 (67.1)                       0.87 (0.44--1.71)                      0.681                              20/30 (66.7)                        77/118 (65.3)                          1.06 (0.46--2.49)                    0.884
  f allele                              51/148 (34.5)                    9/24 (37.5)                        42/124 (33.9)                        1.17 (0.47--2.90                          0.732                                 26/72 (36.1)                           25/76 (32.9)                       1.15 (0.58--2.27)                      0.681                              10/30 (33.3)                        41/118 (34.7)                          0.94 (0.40--2.19)                    0.884
  BsmI genotype                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  BB                                    23 (31.1)                        5 (41.7)                           18 (29.0)                            1.75 (0.49--6.23)                         0.498                                 9 (25.0)                               14 (36.8)                          0.57 (0.21--1.56)                      0.271                              6 (40.0)                            17 (28.8)                              1.65 (0.51--5.34)                    0.533
  Bb                                    38 (51.4)                        4 (33.3)                           34 (54.8)                            0.41 (0.11--1.51)                         0.172                                 22 (61.1)                              16 (42.1)                          2.16 (0.85--5.47)                      0.102                              6 (40.0)                            32 (54.2)                              0.56 (0.18--1.78)                    0.325
  bb                                    13 (17.6)                        3 (25.0)                           10 (16.1)                            1.73 (0.40--7.55)                         0.432                                 5 (13.9)                               8 (21.1)                           0.60 (0.18--2.06)                      0.418                              3 (20.0)                            10 (16.9)                              1.22 (0.29--5.15)                    0.719
  Continued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

By analyzing combined genotypes ([**Table 2**](#Table2){ref-type="table"}), six significant differences were observed after comparing 100% *vs*. \<100% VDR-expression-positive groups. Combined genotypes BbAA (OR=10.0, CI=1.46--68.3, *P*=0.028), bbAa (OR=10.0, CI=1.46--68.3, *P*=0.028), AATt (OR=6.75, CI=1.74--26.1, *P*=0.008), BbAATt (OR=20.3, CI=1.90--217, *P*=0.012), and bbAaTT (OR=10.0, CI=1.46--68.3, *P*=0.028) were more frequent in the former *vs*. the latter group, whereas combined genotype BbAa (OR=0.10, CI=0.01--0.80, *P*=0.010) was less frequent in the former group than the latter.

In comparing the \>20% *vs*. ≤20% VDR-expression-positive groups, combined genotype AaTT (OR=3.89, CI= 0.96--15.8, *P*=0.046) was more frequent in the former than in the latter group.

In comparing absent- *vs*. present-VDR-expression groups, the ApaI-TaqI combined genotype AATT (OR=14.5, CI=1.39--152, *P*=0.025) was more frequent in the melanoma group lacking VDR expression *vs*. the remaining patients.

Considering continuous median percentage values of VDR-expression-positive cells, with 100% VDR-positive cells, significantly higher VDR expression was observed for bbAa (median: 100.0%, range: 15%--100% *vs*. median: 20.0%, range: 0%--100%, *P*=0.029), BbAATt (median: 100.0%, range: 60%--100% *vs*. median: 20.0%, range: 0%--100%, *P*=0.011), bbAaTT (median: 100.0%, range: 15%--100% *vs*. median: 20.0%, range: 0%--100%, *P*=0.029) combined genotype carriers *vs*. non-carriers. By contrast, significantly lower VDR expression was noted for carriers of AATT combined genotype (median: 0.0%, range: 0%--10% *vs*. median; 30.0%, range: 0%--100%, *P*=0.014) *vs*. non-carriers.

Discussion {#s04}
==========

In our study, VDR expression was predominantly assessed in cytoplasm of melanoma cells (79.7%, 59/74 cases), with few tumors (14.9%, 11/74 cases) displaying VDR positivity in the nucleus. Such findings partially contrast those of other studies performed in a Polish cohort of 69 patients with primary cutaneous melanoma (comprising 35 metastatic melanomas and that were classified as follows: 4 Clark I, 6 Clark II, 23 Clark III, 24 Clark IV, and 12 Clark V stage, where 30 were superficial-spreading, 37 were nodular, and two were acral lentiginous melanomas); these previous studies indicated VDR-positive nuclear immunostaining in 84.1% and cytoplasmic immunostaining in 66.7% of patients^[@b38],[@b39]^. The study by Brożyna et al.^[@b39]^, however, showed percentage of melanoma specimens with high nuclear staining at 17.4% (12/69), which is close to the percentage of nuclear staining in our study. Discrepancies between results of Brożyna et al. and our study probably arise from different antibodies employed^[@b21]^, diverse histological characteristics, and/or geographical/genetic backgrounds of melanomas in the respective studies. According to European cancer observatory data ^[@b3]^, the estimated age standardized (European) incidence rate (per 100,000/year) of malignant cutaneous melanoma and mortality are 5.6 and 2.8 in Poland and 13.4 and 2.0 in Italy, respectively.

We further analyzed data regarding cytoplasmic VDR immunohistochemical staining. Once the cytoplasmic VDR binds with 1α, 25-dihydroxyvitamin D ligand, and adequate coreceptor protein, retinoid X receptor, it translocates to the nucleus, and by recruitment of coactivators and corepressors modulates transcription of target genes that encode proteins responsible for final activities induced by vitamin D hormonal signaling^[@b18]^. Consequently, absence or down-regulation of VDR expression may present implications for vitamin D resistance in melanoma tissues^[@b38],[@b48],[@b49]^ and potentially modulates effects of vitamin D supplementation on prevention therapy of melanoma patients^[@b49],[@b50]^.

We did not observe effects of age at melanoma diagnosis and gender on VDR expression in cutaneous melanomas^[@b45]^. Roles of BMI and smoking were focuses of previous melanoma research^[@b8],[@b25],[@b51]^. In the present investigation, we did not observe the effects of BMI and smoking on VDR expression.

Consistent with studies performed by other authors on a Polish cohort^[@b38],[@b39]^, we observed that stage I melanomas were more frequent in tumors with high than with low VDR expression. In our study, stage IIA invasion was particularly more frequent in melanomas lacking VDR expression than in melanomas showing VDR expression. However, we did not observe significant data in relation to metastatic stages III and IV. Causes of these findings will require further enlarged studies.

Overall, metastatic melanomas did not exhibit different VDR expression from non-metastatic melanomas. Such results agreed with observations of some studies^[@b13],[@b20],[@b48]^ but contradicted the findings of other authors^[@b38],[@b39]^. Specific geographical/ethnic backgrounds possibly affected results. Thus, enlarged studies in subjects with different ethnicities should be performed in the future to substantiate this issue.

In our study, localization of melanoma on the body was unrelated with VDR expression. We only observed a tendency (*P*=0.093) for upper limb melanomas to be more frequent in tumors lacking VDR expression. Thus, despite the expected different exposures to sunlight and environmental factors of different parts of the human body, VDR expression in our study is not associated with body regions in which primary melanomas develop.

Lesion-specific characteristics did not correlate with VDR expression; these characteristics include ulceration, number of mitotic figures, regression, absence of TILs, non-brisk or brisk TILs, tumor emboli, and melanoma subtype (epithelioid and small cell). At variance, in Polish patients studied by Brożyna and colleagues^[@b39]^ cytoplasmic VDR immunostaining was higher in group of brisk TIL-positive *vs*. that of absent and non-brisk TIL melanomas (*P*=0.01), and VDR expression was lower in melanomas with ulceration. We noted a tendency for higher frequency of superficial spreading (*P*=0.063) in melanomas with high than low VDR expression. Similarly, Brożyna and colleagues^[@b38]^ observed higher VDR expression in superficially spreading than nodular melanomas.

Remarkably, VDR expression was related to tumor Breslow thickness and Clark levels in our Italian patients. Melanomas with a thickness below 1.00 mm were more frequently observed in cases with high than low VDR expression, whereas those with thickness of over or equal to 1.01 mm were more frequent in melanomas with low VDR expression. Clark level II (none of the studied melanomas presented a Clark I) was detected more frequently in melanomas with high than low VDR expression (*P*=0.025). Overall, such findings concur with previous data on Polish patients^[@b38],[@b39]^.

We observed that VDR expression was unrelated with the presence of multiple melanomas, additional non-melanoma skin cancers and non-skin cancers, and melanoma familiarity. To our knowledge, no previous study assessed these issues.

To our knowledge, our study was the first to investigate the relationship between VDR expression of human melanoma cells in excised tissues of patients and *VDR* polymorphisms. Out of four *VDR* polymorphisms investigated in our study, individual SNPs of FokI, BsmI, and TaqI did not display any relation with expression of VDR in melanoma. Only the ApaI genotype was correlated to VDR expression in melanoma. The heterozygous genotype Aa was identified in 61.1% of melanomas with high VDR expression *vs*. 36.8% of melanomas with low VDR expression (OR=2.69, *P*=0.037). A allele was more frequent in 100% than \<100% VDR-positive cells (OR=3.16, *P*=0.038). To our knowledge, no research studied the role of *VDR*-ApaI polymorphism in VDR expression in melanoma tissues. *VDR*-ApaI SNP is located in an intron sequence and thus cannot directly modify the amino acid sequence of VDR protein; however, it participates in VDR RNA processing^[@b26]^. Recent evidence demonstrated that intronic sites of the VDR gene can function as binding sites of transcriptional regulators, such as p53^[@b52],[@b53]^. A meta-analysis study^[@b35]^ indicated that *VDR*-ApaI polymorphism of the European population features an association with overall skin cancer risk (Aa *vs*. AA, OR=1.27, CI=1.05--1.53; Aa+aa *vs*. AA, OR=1.23, CI=1.04--1.47). In a recent Italian study, the Aa heterozygous genotype was associated with increased risk of lumbar pathologies, especially osteochondrosis^[@b29]^.

A number of combined genotypes in our study yielded significant findings according to VDR expression. The AaTT combined genotype was more frequent in melanomas with high than low VDR expression. Combined genotypes BbAA, bbAa, AATt, BbAATt, and bbAaTT were more frequent in 100% VDR-positive cells than \<100% VDR-positive cells. The AATT combined genotype was much more frequent in subjects without VDR expression (20%) than in those with VDR expression (1.7%) (OR=14.5, *P*=0.025). No previous study investigated the relationship of VDR expression with *VDR* combined genotypes. Lack of VDR expression in excised melanoma tissues has been associated with reduced overall survival of patients^[@b38],[@b39]^. Therefore, melanoma prognosis may be influenced by carrying a *VDR* combined genotype associated to absent or reduced VDR expression. In our melanoma patients, AATT is a rare combined genotype with a frequency of 5.4%, which is similar to the recent finding in an Italian cohort of 518 non-oncological subjects (6.0%) ^[@b29]^. Further enlarged studies are warranted to assess roles of ApaI, BsmI, and TaqI combined genotypes in VDR expression in melanomas and their prognosis.

Regulation of VDR abundance is an important modulation mechanism of cellular responsiveness to 1α, 25-dihydroxyvitamin D^[@b10]^. Mechanisms underlying regulation of VDR abundance include alterations in transcription rate of VDR gene and/or stability of VDR mRNA and epigenetic changes^[@b14],[@b18],[@b54]^. Interestingly, treatment with calcitriol can enhance VDR mRNA in cultured melanoma cells, showing that increasing vitamin D consumption can induce VDR expression^[@b14]^. On the other hand, enhanced melanogenesis was associated with downregulation of VDR ex-pression^[@b38],[@b55],[@b56]^. Response of melanoma cells to calcitriol corresponds to expression level of VDR mRNA, which in turn may be regulated by VDR miRNAs and by epigenetically modulating drugs^[@b50]^. Remarkably, recent evidence suggests that tumor suppressors, such as p53, are implicated on direct regulation of VDR^[@b53]^. Molecules other than vitamin D, such as curcumin and vitamin E derivatives, were indicated as novel VDR ligands^[@b19],[@b57]^, whereas vitamin A derivatives were suggested as modulators of VDR actions^[@b58]^. Given the wide variety of positive and negative VDR modulators, each individual expression of VDR is highly dynamic in cells, with nuclear translocation of VDR fluctuating upon instant induction^[@b18],[@b19],[@b22]^. We speculate that unresponsiveness of some cutaneous melanomas to anti-proliferative effects of vitamin D possibly resulted from absence or insufficient VDR expression in melanoma and/or melanocytic cells. Further human studies are warranted to assess whether benefits of vitamin D augmentation are modulated by VDR expression in melanoma/melanocytic cells and/or by carriage of a specific *VDR* genotype and/or combined genotype polymorphisms that affect VDR expression. Such factors can modulate dose requirement of vitamin D treatments^[@b59]^.

Roles of vitamin D in skin cancers still require complete elucidation^[@b10],[@b57]^. All vitamin D actions virtually occur through VDR activation. Recent evidence shows that the effects of 1α, 25-dihydroxyvitamin D and VDR are mediated at least in part by cellular calcium levels; thus, calcium possibly contributes to the suppressive ability of VDR on skin cancer^[@b10],[@b57]^. Deletion of VDR notably results in an increased susceptibility to tumorigenesis and also reduces ability of keratinocytes to clear UVB-induced DNA mutations^[@b57]^. VDR can bind to thousands of VDREs on human genome and up- or downregulate hundreds of genes^[@b10],[@b30],[@b57]^. Based on bioinformatic analysis, almost 15,000 sites in human DNA are bound by VDR, and 16%--21% of these putative binding sites are found at gene promoters^[@b10],[@b57],[@b60]^. Aside from classical VDRE-mediated mechanisms, increasing evidence point to regulatory contribution of several miRNAs^[@b14],[@b18],[@b54]^ and long non-coding RNAs^[@b10],[@b57]^. A recent study on VDR cistrome demonstrated the unexpected complexity of gene regulation, which was examined on a genome-wide scale in target tissues and cells, including a cross-talk between VDR and immune factors^[@b60],[@b61]^. VDR expression is also commonly and significantly down regulated in colon adenocarcinoma. VDR cistrome analyses suggested that reduced VDR expression in colon cancer changes VDR activity by dampening expression of tumor suppressors by either stabilizing or inhibiting down regulation of oncogene expression. In turn, these effects may be associated with severe patient outcomes^[@b62]^. Thus, further research should study complex gene interactions and biological pathways related to vitamin D and melanoma and combine clinical evidence with molecular findings to support further progress^[@b57],[@b60],[@b61]^.

Limitations of our study include the limited number of patients and absence of data on circulating vitamin D levels in patients at the time of melanoma excision. Strengths of this research comprise genetic background restrictions of enrolled patients and determination of demographic, lifestyle, histological, and genetic characteristics.

Given the sample size and multiple comparisons of our study, a validation of independent datasets with larger samples, and multivariable analysis will be necessary to adjust genetic traits for age, sex, tumor location, sun exposure, and smoking. Serum sampling in future studies may also be performed to determine circulating levels of vitamin D at time of melanoma excision.

Conclusions {#s04.01}
-----------

Current information insufficiently discusses influence of vitamin D oral supplementation to direct VDR modulatory effects in human skin cells, including melanocytes and keratinocytes. Our present findings support the necessity of further studies on this issue by combining clinical and molecular approach.

Our study showed that VDR expression is associated with prognostic parameters of tumor Breslow thickness and Clark level. However, VDR expression was not related to metastatic melanomas. Our immunohistochemical results concur with those of a previous study on VDR expression in colorectal cancer, showing that VDR was not associated with tumor location, stage, and grade^[@b42]^, and with another lung tumor study which demonstrated high variability of VDR expression^[@b43]^. Interestingly, we observed correlation between the Aa genotype and AaTT combined genotype with higher level of VDR expression and between AATT combined genotype and low or absent VDR expression; this new finding will require further validation. Future studies should assess whether VDR expression and *VDR* combined genotypes affect benefits of vitamin D and can drive an appropriate dose and schedule of calcitriol or other active (low calcemic) vitamin D analogs for melanoma treatment. Future set up of personalized nutrition and behavioral interventions will benefit from molecular studies exploring the connection of biological pathways to bioactive components of food and cancer^[@b63]^. Our study suggests that determination of VDR expression in excised tissues of melanoma and/or determination of *VDR* genotypes carriage can be used as personalized tool of precision medicine when considering melanoma patients.
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